Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
DiaMedica Therapeutics, Inc. (DMAC) had Normalized Income after Taxes of $-32.77M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-32.77M |
|
-- |
|
-- |
|
$34.40M |
|
$-34.40M |
|
$1.66M |
|
$-32.74M |
|
$-32.74M |
|
$-32.77M |
|
$-32.77M |
|
$-32.77M |
|
|
Normalized Income after Taxes |
$-32.77M |
$-34.40M |
|
$-35.30M |
|
46.98M |
|
46.98M |
|
$-0.70 |
|
$-0.70 |
|
| Balance Sheet Financials | |
$60.63M |
|
$0.14M |
|
$0.74M |
|
$61.37M |
|
$5.13M |
|
$0.00M |
|
$0.13M |
|
$5.26M |
|
$56.11M |
|
$56.11M |
|
$56.11M |
|
53.74M |
|
| Cash Flow Statement Financials | |
$-29.06M |
|
$-2.19M |
|
$43.88M |
|
$3.02M |
|
$15.65M |
|
$12.62M |
|
$3.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.81 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-58.40% |
|
-58.40% |
|
-53.39% |
|
-58.39% |
|
$1.04 |
|
$-0.62 |
|
$-0.62 |
|